A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors (COBRA)

NCT00849550 Phase 1 COMPLETED

The purpose of this study is to determine if RAD001 (everolimus) helps improve the standard treatment of XELOX-A (bevacizumab, oxaliplatin, capecitabine) in advanced solid tumors.

Details

Lead sponsor	Herbert Hurwitz
Phase	Phase 1
Status	COMPLETED
Enrolment	32
Start date	2009-07
Completion	2012-12

Conditions

• Unspecified Adult Solid Tumor, Protocol Specific
• Cancer

Interventions

• capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)

Primary outcomes

• To determine the MTD/RPTD of capecitabine/oxaliplatin/bevacizumab/everolimus (XELOX-A-Ev) for subjects with advanced solid tumors. — End of treatment phase

Countries

United States